Skip to main content
. 2022 Mar 28;14:1267–1281. doi: 10.2147/CMAR.S351383

Figure 5.

Figure 5

The comparison of PD-1-expression T cells determined by mean fluorescence intensity (MFI) in peripheral blood of RRMM patients before and after 5 cycles of daratumumab treatment. The central line shows the median.